Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
Lineage Cell Therapeutics, Inc. (LCTX)
Company Research
Source: Business Wire
Initial Program Focus Will Be On Addressing Manufacturing Scale CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the initiation of a new islet cell transplant program in Type 1 Diabetes (T1D). Specifically, the company aims to deploy its manufacturing capability to address the issue of large-scale production of islet cells, with the initial goal of establishing a production modality that can support the entire production process in a dynamic culturing system, potentially solving a major hurdle to commercialization of islet cell therapy product candidates.“Recent and emerging evidence suggests that an islet cell transplant may be able to provide the equivalent of a functional cure for some people with diabetes. Several islet cell programs for T1D have reached phase 1 clinical trials, b
Show less
Read more
Impact Snapshot
Event Time:
LCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LCTX alerts
High impacting Lineage Cell Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LCTX
News
- Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy [Seeking Alpha]Seeking Alpha
- Dimension Bio Announces Inaugural Clinical and Scientific Advisory BoardsPR Web
- Lineage Cell Therapeutics Inc (LCTX) Q3 2025 Earnings Call Highlights: Strategic Partnerships ... [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics GAAP EPS of -$0.13 misses by $0.10, revenue of $3.68M beats by $1.38M [Seeking Alpha]Seeking Alpha
- Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire